IASLC-TTLC 2022 - IASLC 2022 Targeted Therapies of Lung Cancer Meeting
Feb 22 - Feb 26, 2022 | Santa MonicaCAUS
LARVOL is not affiliated with IASLC 2022 Targeted Therapies of Lung Cancer Meeting and all trademarks, logos, and brand names are property of their respective owners
Showing 5 abstracts linked to Trials
Phase II Study of Lorlatinib in Patients with ROS1-Rearranged Lung Cancer with CNS Progression on Crizotinib
Trial in Progress: Phase II Study of Bevacizumab in Combination with Chemoimmunotherapy Followed by Maintenance Bevacizumab plus Atezolizumab in Patients with Extensive-Stage Small Cell Lung Cancer and Liver Metastases.
ART1, an Extracellular mono-ADP-ribosyltransferase Promotes Lung Cancer Growth by Triggering Immuneresistance and is Upregulated in Response to Cellular Stress
Pembrolizumab and Weekly Low Dose Carboplatin and Paclitaxel Compared with Pembrolizumab Alone in Patients with NSCLC and Poor PS
Antitumor Activity of KIN-2787, a Next-Generation pan-RAF Inhibitor, in Preclinical Models of Human BRAF-alteration Driven Non-small Cell Lung Cancer (NSCLC)